Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00683904
First received: May 22, 2008
Last updated: March 15, 2011
Last verified: March 2011
  Purpose

The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer as First-line Treatment

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Number of Participants With Dose-limiting Toxicity (DLT) [ Time Frame: Days 1 through 21 (Cycle 1) ] [ Designated as safety issue: Yes ]
    DLT is defined as any of the following: Common Terminology Criteria (CTC), Version 3, Grade(Gr) 4 neutropenia (absolute neutrophil count <500 cells/mm^3) for at least 5 days or febrile neutropenia; Gr 4 thrombocytopenia (<25,000 cells/mm^3 or bleeding needing platelet transfusion); Gr 3 or 4 nausea, vomiting, or diarrhea, despite medical intervention; any other drug-related Gr 3 or 4 nonhematologic toxicity, except Gr 3 injection site reaction, fatigue/asthenia, transient arthralgia/myalgia, or transient electrolytes abnormal. Gr 1=Mild; Gr 2=Moderate; Gr 3=Severe; Gr 4=Life-threatening.

  • Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of Carboplatin in Combination With Ixabepilone, 32 mg/m^2 [ Time Frame: Days 1 through 21 (Cycle 1) ] [ Designated as safety issue: Yes ]
    The MTD was defined as the highest dose evaluated for which less than one sixth of patients experience a DLT in Cycle 1. The recommended phase 2 dose is the MTD defined in Cycle 1, with consideration given to chronic cumulative toxicity occurring at later cycles.


Secondary Outcome Measures:
  • Number of Participants With Death as Outcome, Treatment-related Serious Adverse Events (SAEs), SAEs, Adverse Events (AEs), and Treatment-related AEs Leading to Discontinuation [ Time Frame: Days 1 through 21 (Cycle 1) ] [ Designated as safety issue: Yes ]
    An SAE is any untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongs existing hospitalization. An AE is any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related comprises certainly, probably, and possibly related and of unknown relationship to study drug.

  • Number of Participants With Grade 3 or Greater Treatment-related AEs [ Time Frame: Days 1 through 21 (Cycle 1) ] [ Designated as safety issue: Yes ]
    An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment. AEs graded according to CTC, Version 3.0. Gr 1=Mild; Gr 2=Moderate; Gr 3=Severe; Gr 4=Life-threatening. Treatment-related comprises certainly, probably, and possibly related and of unknown relationship to study drug.

  • Number of Participants With Abnormalities in Hematology Laboratory Values by Worst CTC Grade [ Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days) ] [ Designated as safety issue: Yes ]

    LLN=lower level of normal; ULN=upper level of normal. Hemoglobin (g/dL; LLN=11.3; ULN=14.9); leukocytes (*10^3 c/uL; LLN=4.1; ULN=6.1); lymphocytes (*10^3 c/uL); neutrophils (absolute), neutrophils + bands (*10^3 c/uL); platelet count (*10^9 c/L; LLN=131; ULN=365)

    Appendix 7.1.2


  • Number of Participants With Abnormalities in Serum Chemistry Laboratory Values by Worst CTC Grade [ Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days) ] [ Designated as safety issue: Yes ]
    ULN=upper limit of normal; LLN=lower limit of normal. Alkaline phosphatase=ALP(LLN=115; ULN=359) (U/L); alanine aminotransferase=ALT (LLN=8; ULN=42)(U/L); aspartate aminotransferase=AST (LLN=13; ULN=33) (U/L); albumin (LLN=3.7; ULN=5.2)(g/dL); bilirubin (LLN=0.3; ULN=1.2)(mg/dL); calcium (LLN=8.7; ULN=10.3)(mg/dL); creatinine (LLN=0.6; ULN=1.1)(mg/dL); potassium (LLN=3.6; ULN=4.9) (mEq/L); sodium (LLN=138; ULN=146) (mEq/L)

  • Number of Participants With Abnormalities in Urine Testing Results by Worst CTC Grade [ Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days) ] [ Designated as safety issue: Yes ]
    Toxicities graded according to CTC, Version 3. Protein Gr 1: <1.0 g/24 hrs (1+); Gr 2: 1.0 to 3.4 g/24 hrs (2+ to 3+ ); Gr 3: >=3.5 g/24 hrs (4+); Gr 4: Nephrotic syndrome. Note: + = qualitative measure of urine chemistry.

  • Number of Participants With Abnormalities in Blood Pressure and Heart Rate [ Time Frame: At screening and Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22) ] [ Designated as safety issue: Yes ]
    Blood pressure and heart rate obtained before ixabepilone infusion, every 1 hour during and at the end of ixabepilone infusion, and at the end of carboplatin infusion in Cycle 1. For subsequent cycles, vital signs obtained before ixabepilone infusion, at the end of ixabepilone infusion, and at the end of carboplatin infusion. Any new or worsening clinically significant changes since last entry were recorded as appropriate AE or SAE.

  • Number of Participants With Abnormalities in Weight and Eastern Cooperative Oncology Group (ECOG) Performance Status [ Time Frame: At screening of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22) ] [ Designated as safety issue: Yes ]
    Participants weighed same day as serum chemistry tests. Body surface area recalculated only if body weight changes >10%. ECOG criteria used to assess disease progression and affects on daily living abilities and to determine appropriate treatment and prognosis. Grade 1=Restricted physical activity but ambulatory and capable of light work; Grade 2=Ambulatory, capable of self care, but unable to carry out any work activities; Grade 3=Capable of limited self care, confined to bed or chair 50% or more of waking hours; Grade 4=Completely disabled, totally confined to bed or chair.

  • Number of Participants at Each Response Evaluation Criteria in Solid Tumors (RECIST) Assessment [ Time Frame: Days 1 through 21 (Cycle 1) ] [ Designated as safety issue: No ]
    Tumor response was assessed using the RECIST assessment: Complete response (CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial response (PR)=At least 30% reduction in the sum of the longest diameters of all target lesions; Progressive disease (PD)=At least 20% increase in the sum of the longest diameters of all target lesions; Stable disease (SD)=Neither PR nor PD criteria were met.

  • Maximum Observed Plasma Concentration of Ixabepilone [ Time Frame: Days 1 to 8 of Cycle 1 (21 days) ] [ Designated as safety issue: No ]
  • Time of Maximum Observed Plasma Concentration of Ixabepilone [ Time Frame: Days 1 to 8 of Cycle 1 (21 days) ] [ Designated as safety issue: No ]
  • Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time of Ixabepilone [ Time Frame: Days 1 to 8 of Cycle 1 (21 days) ] [ Designated as safety issue: No ]
  • Volume of Distribution at Steady State of Ixabepilone [ Time Frame: Days 1 to 8 of Cycle 1 (21 days) ] [ Designated as safety issue: No ]
  • Total Body Clearance of Ixabepilone [ Time Frame: Days 1 to 8 of Cycle 1 (21 days) ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: June 2008
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Other Names:
  • IXEMPRA
  • BMS-247550
Active Comparator: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥20 years
  • Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)
  • Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent
  • No prior chemotherapy-containing regimens for the treatment of NSCLC
  • Eastern Cooperative Oncology Group performance status of 0-1
  • Life expectancy of at least 12 weeks
  • Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1
  • Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy)

Exclusion Criteria:

  • Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug
  • Women pregnant or breast feeding
  • Women with a positive pregnancy test result on enrollment or prior to study drug administration
  • Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP
  • Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases
  • Prior radiation must not have included ≥30% of major bone-marrow-containing areas (pelvis, lumbar spine)
  • Common Terminology Criteria (CTC) Grade 2 or greater neuropathy
  • Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements
  • Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible)
  • Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy.
  • Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months
  • Known history of infection with human immunodeficiency virus
  • Inadequate bone marrow function
  • Inadequate hepatic function
  • Inadequate renal function
  • Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL
  • Known severe hypersensitivity reaction to agents containing carboplatin and other platinum
  • Prior treatment with an epothilone and/or with platinum
  • History of high-dose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years
  • On treatment with strong Cytochrome P450 3A4 inhibitor
  • Current imprisonment
  • Compulsorily detention for treatment of psychiatric or physical illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00683904

Locations
Japan
Local Institution
Chuo-Ku, Tokyo, Japan, 104-0045
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00683904     History of Changes
Other Study ID Numbers: CA163-160
Study First Received: May 22, 2008
Results First Received: February 8, 2011
Last Updated: March 15, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Carboplatin
Epothilones
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 22, 2014